Skip to main content

Advertisement

SpringerLink
Log in

Health Maintenance and Inflammatory Bowel Disease

  • Large Intestine (B Cash, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Inflammatory bowel disease (IBD) patients, specifically those with Crohn’s disease and ulcerative colitis, are at an increased risk of developing adverse events either related to disease course or therapeutic interventions. These risks can be mitigated by ensuring the patient is current on all aspects of their general health maintenance. This article is intended to serve as a guide regarding the health maintenance issues of the patient with IBD with recommendations for screening and surveillance intervals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventative care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56:819–24.

    Article  PubMed  Google Scholar 

  2. Di Palma JA, Farraye FA. Crohn’s disease: the first visit. Gasteroenterol Hepatol. 2011;7:163–9. An important review for the initiation and titration of immunomodulating medications.

    Google Scholar 

  3. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135–9.

    Article  PubMed  Google Scholar 

  4. Knox DL, Schachat AP, Mustonen E. Primary, secondary, coincidental ocular complications of Crohn’s disease. Ophthalmology. 1984;91:163–73.

    Article  PubMed  CAS  Google Scholar 

  5. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Opthalmol. 1982;14:256–360.

    Google Scholar 

  6. Manolakis C, Farraye FA, Di Palma JA. Crohn’s disease: the subsequent visit. Gastroenterol Hepatol. 2013;9:17–20.

    Google Scholar 

  7. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2, CD008794.

    PubMed  Google Scholar 

  8. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9. Important information regarding adverse effects of therapy; differs from what was previously reported.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for nonmelanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:152–6.

    Article  PubMed  Google Scholar 

  12. Targownik L, Bernstein C, Nugent Z, Leslie W. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013;11:278–85. Interesting pathophysiologic review of osteoporosis in IBD.

    Article  PubMed  Google Scholar 

  13. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250–6.

    Article  PubMed  CAS  Google Scholar 

  14. Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner. 1993;23:95–104.

    Article  PubMed  CAS  Google Scholar 

  15. Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108:417–22.

    Article  Google Scholar 

  16. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684–94.

    Article  PubMed  CAS  Google Scholar 

  18. Driscoll Jr RH, Meredith SC, Sitrin M, et al. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology. 1982;83:1252–8.

    PubMed  Google Scholar 

  19. Krawitt EL, Beeken WL, Janney CD. Calcium absorption in Crohn’s disease. Gastroenterology. 1976;71:251–4.

    PubMed  CAS  Google Scholar 

  20. Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935–42.

    Article  PubMed  CAS  Google Scholar 

  21. Silvennoinen J, Lamberg-Allardt C, Kakkainen M, et al. Dietar calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240:285–92.

    Article  PubMed  CAS  Google Scholar 

  22. Vagianos K, Bector S, Mcconnell J, et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31:311–9.

    Article  PubMed  CAS  Google Scholar 

  23. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631–6.

    Article  PubMed  Google Scholar 

  24. Sing TT, Demets AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case–control study. Gastroenterology. 2009;136:451–8.

    Article  Google Scholar 

  25. Sinclair J, Wasan S, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin N Am. 2012;41:325–37.

    Article  Google Scholar 

  26. Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis. 2008;14 suppl 2:S14–5.

    Article  PubMed  Google Scholar 

  27. Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol. 1998;10:821–5.

    Article  PubMed  CAS  Google Scholar 

  28. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity and comorbity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15:1399–409.

    Article  PubMed  Google Scholar 

  30. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 suppl 1:36–58.

    Article  Google Scholar 

  31. Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003;327:1144–6.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Graff L, Walker J, Bernstein C. It’s not just about the gut: managing depression and anxiety in inflammatory bowel disease. Pract Gastroenterol. 2011;62:11–25.

    Google Scholar 

  33. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.

    Article  PubMed  CAS  Google Scholar 

  34. Pai M, Zwerling A, Menziers D. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619–33.

    Article  PubMed  CAS  Google Scholar 

  36. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–40.

    Article  PubMed  Google Scholar 

  37. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17:2536–40.

    Article  PubMed  Google Scholar 

  38. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261–8.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of innumosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042–7.

    Article  PubMed  Google Scholar 

  40. Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60:456–62.

  41. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8.

    Article  PubMed  Google Scholar 

  42. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States. Ann Intern Med. 2012;156:211–7.

    Article  Google Scholar 

  43. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–9. Evolving information regarding live vaccines.

    PubMed  CAS  PubMed Central  Google Scholar 

  44. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1–30.

    PubMed  Google Scholar 

  45. Kotton CN. Nailing down the shingles in IBD. Inflamm Bowel Dis. 2007;13:1178–9.

    Article  PubMed  Google Scholar 

  46. Singh A, Englund K. Q: who should receive the shingles vaccine? Cleve Clin J Med. 2009;76:48–8.

    Google Scholar 

  47. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States. Ann Intern Med. 2009;150:40–4.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Catherine S. Manolakis and Brooks D. Cash have nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, University of South Alabama College of Medicine, 75 S. University Boulevard, Suite 6000-B, Mobile, AL, 36688, USA

    Catherine S. Manolakis & Brooks D. Cash

Authors
  1. Catherine S. Manolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brooks D. Cash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brooks D. Cash.

Additional information

This article is part of the Topical Collection on Large Intestine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manolakis, C.S., Cash, B.D. Health Maintenance and Inflammatory Bowel Disease. Curr Gastroenterol Rep 16, 402 (2014). https://doi.org/10.1007/s11894-014-0402-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-014-0402-4

Keywords

Search

Navigation